EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ICU Medical's enterprise value is $3,785 Mil.
ICU Medical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $2,259 Mil. Therefore, ICU Medical's EV-to-Revenue for today is 1.68.
The historical rank and industry rank for ICU Medical's EV-to-Revenue or its related term are showing as below:
ICUI'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.56 Med: 3.27 Max: 6.22
Current: 1.68
During the past 13 years, the highest EV-to-Revenue of ICU Medical was 6.22. The lowest was 1.56. And the median was 3.27.
ICUI's EV-to-Revenue is ranked better than 68.52% of 826
companies
in the Medical Devices & Instruments industry
Industry Median: 2.925
vs ICUI: 1.68
As of today (2024-04-19), ICU Medical's stock price is $96.92.
ICU Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $93.56. Therefore, ICU Medical's PS Ratio for today is 1.04.
ICU Medical EV-to-Revenue Historical Data
The historical data trend for ICU Medical's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
ICU Medical Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
2.86
3.27
3.44
2.32
1.71
ICU Medical Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
2.32
2.35
2.54
1.95
1.71
Competitive Comparison
For the Medical Instruments & Supplies subindustry, ICU Medical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical EV-to-Revenue Distribution
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where ICU Medical's EV-to-Revenue falls into.
ICU Medical's current Enterprise Value is $3,785 Mil.
ICU Medical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,259 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical's share price for today is $96.92.
ICU Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $93.56.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of ICU Medical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017, and Smiths Medical from Smiths Group in 2022. It holds top-tier positions in its original reporting segments: infusion consumables (25% of 2022 revenue), IV solutions (16%), infusion systems (15%), and critical care (2%) as well as its new Smiths segments: Smiths infusion systems (15%), vascular access (14%), and vital care (12%). The combined entity remains primarily U.S. focused, generating over 64% of its sales domestically.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ICUI has been successfully added to your 